Otros idiomas Provectus Biopharmaceuticals, Inc.

Acciones

PVCT

US74373P1084

Mercado cerrado - OTC Markets Otros sitios de cotización 21:57:37 10/05/2024			Varia. Cinco días.	Varia. 1 de enero.
0,1943 ^USD	-0,82 %		+0,62 %	+102,40 %

18/04	Provectus Biopharmaceuticals anuncia la publicación de datos preclínicos de la administración oral de rosa de Provectus	CI
16/04	Provectus Biopharmaceuticals, Inc. nombra presidente a Dominic Rodrigues	CI

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Provectus Biopharmaceuticals Announces Notice of Allowance for U.S. Patent of Oral Administration of Rose Bengal Sodium in Hematology (Leukemia)	02/05
Provectus Biopharmaceuticals Announces Publication of Preclinical Data of Oral Administration of Provectus Rose Bengal for Solid Tumor Cancers	18/04
Provectus Biopharmaceuticals Announces Publication of Preclinical Data of Oral Administration of Provectus Rose	18/04
Provectus Biopharmaceuticals Announces Management Additions and Reiterates Commitment to Shareholder Value Creation	16/04
Provectus Biopharmaceuticals, Inc. Appoints Dominic Rodrigues as President	16/04
Provectus Biopharmaceuticals, Inc. Appoints Ed Pershing as Chief Executive Officer	16/04
Provectus Biopharmaceuticals Announces Presentation of Cancer Immunotherapy PV-10 Poster for HNSCC at AACR 2024 Annual Meeting	11/04
Provectus Biopharmaceuticals, Inc. Announces Presentation of Cancer Immunotherapy PV-10 Poster for HNSCC at AACR 2024 Annual Meeting	11/04
Provectus Biopharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03
Provectus Biopharmaceuticals Announces Exclusive Worldwide License Agreement with University of Miami for Photodynamic Antimicrobial Treatment of Different Eye Infections with Rose Bengal Sodium	27/03
Provectus Biopharmaceuticals, Inc. Announces Exclusive Worldwide License Agreement with University of Miami for Photodynamic Antimicrobial Treatment of Different Eye Infections with Rose Bengal Sodium	27/03
Provectus Biopharmaceuticals, Inc. Announces Management Changes	26/03
Provectus Biopharmaceuticals Announces Notices of Allowance and Award for U.S. Patents of Rose Bengal Sodium in Virology, Pediatric Solid Tumor Cancers, and Vaccines	12/03
Provectus Biopharmaceuticals Announces Acceptance of Cancer Immunotherapy PV-10 Abstract for HNSCC at AACR 2024 Annual Meeting	07/03
PROVECTUS BIOPHARMACEUTICALS ANNOUNCES ACCEPTANCE OF PHARMACEUTICAL-GRADE ROSE BENGAL SODIUM ABSTRACT FOR POSTER PRESENTATION AT 2024 SOCIETY FOR INVESTIGATIVE DERMATOLOGY ANNUAL MEETING	01/03
Provectus Biopharmaceuticals Announces Acceptance of Pharmaceutical-Grade Rose Bengal Sodium Abstract for Poster Presentation at 2024 Society for Investigative Dermatology (SID) Annual Meeting	29/02
Provectus Biopharmaceuticals Announces First Quarter 2024 Conference Call	15/02
Provectus Biopharmaceuticals Engages irlabs for Investor Relations Services	14/02
Provectus Biopharmaceuticals Announces Notice of Allowance of First U.S. Patent of Rose Bengal Sodium for Use as Anticancer and Antiviral Vaccine Adjuvant	18/12
Provectus Biopharmaceuticals Provides Updated Data on Cancer Immunotherapy PV-10 for Advanced Cutaneous Melanoma	15/11

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Provectus Biopharmaceuticals, Inc.

Acciones

PVCT

US74373P1084

Otros idiomas

Filtros